Giuseppina Barrera
Overview
Explore the profile of Giuseppina Barrera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1799
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cucci M, Grattarola M, Monge C, Roetto A, Barrera G, Caputo E, et al.
Antioxidants (Basel)
. 2023 Jun;
12(6).
PMID: 37372043
The use of specific inhibitors towards mutant BRAF (BRAFi) and MEK (MEKi) in BRAF-mutated patients has significantly improved progression-free and overall survival of metastatic melanoma patients. Nevertheless, half of the...
2.
Azzimonti B, Ballacchino C, Zanetta P, Cucci M, Monge C, Grattarola M, et al.
Antioxidants (Basel)
. 2023 Mar;
12(3).
PMID: 36978794
Mounting evidence indicates that the microbiota, the unique combination of micro-organisms residing in a specific environment, plays an essential role in the development of a wide range of human diseases,...
3.
Sequera C, Grattarola M, Holczbauer A, Dono R, Pizzimenti S, Barrera G, et al.
Cell Death Dis
. 2022 Nov;
13(11):994.
PMID: 36433941
Enhanced activation of the transcription factor MYC and of the receptor tyrosine kinase MET are among the events frequently occurring in hepatocellular carcinoma (HCC). Both genes individually act as drivers...
4.
Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies
Pizzimenti S, Ribero S, Cucci M, Grattarola M, Monge C, Dianzani C, et al.
Antioxidants (Basel)
. 2021 Dec;
10(12).
PMID: 34943045
Melanoma is a highly aggressive cancer with the poorest prognosis, representing the deadliest form of skin cancer. Activating mutations in BRAF are the most frequent genetic alterations, present in approximately...
5.
Muzio G, Barrera G, Pizzimenti S
Antioxidants (Basel)
. 2021 Nov;
10(11).
PMID: 34829605
Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor superfamily. Originally described as "orphan nuclear receptors", they can bind both natural and synthetic ligands acting as agonists or antagonists....
6.
Grattarola M, Cucci M, Roetto A, Dianzani C, Barrera G, Pizzimenti S
Free Radic Biol Med
. 2021 Aug;
174:202-210.
PMID: 34364982
The intrinsic chemoresistance of pancreatic ductal adenocarcinoma (PDAC) represents the main obstacle in treating this aggressive malignancy. It has been observed that high antioxidant levels and upregulated Nrf2 and the...
7.
Barrera G, Cucci M, Grattarola M, Dianzani C, Muzio G, Pizzimenti S
Antioxidants (Basel)
. 2021 Apr;
10(4).
PMID: 33805928
Chemoresistance represents the main obstacle to cancer treatment with both conventional and targeted therapy. Beyond specific molecular alterations, which can lead to targeted therapy, metabolic remodeling, including the control of...
8.
Dianzani C, Zara G, Maina G, Pettazzoni P, Pizzimenti S, Rossi F, et al.
Biomed Res Int
. 2021 Mar;
2021:6158298.
PMID: 33644227
[This corrects the article DOI: 10.1155/2014/895986.].
9.
Ambrosio L, Argenziano M, Cucci M, Grattarola M, de Graaf I, Dianzani C, et al.
Antioxidants (Basel)
. 2020 Oct;
9(10).
PMID: 33066634
The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) is considered as the master regulator of antioxidant and cytoprotective gene expressions. Moreover, it plays a pivotal role in cancer...
10.
Cucci M, Grattarola M, Dianzani C, Damia G, Ricci F, Roetto A, et al.
Free Radic Biol Med
. 2020 Feb;
150:125-135.
PMID: 32101771
Chemoresistance represents one of the main obstacles in treating several types of cancer, including bladder and ovarian cancers, and it is characterized by an increase of cellular antioxidant potential. Nrf2...